Orencia (Abatacept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Orencia (Abatacept) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, a growing demand for biologic therapies, the introduction of new formulations like subcutaneous abatacept for easier administration, rising awareness, and early diagnosis of autoimmune conditions, as well as expanding healthcare access.

Market growth during the forecast period is expected to be driven by the increasing adoption of personalized medicine, growing patient preference for less invasive subcutaneous administration, expansion in emerging markets with improved healthcare access, and the ongoing shift toward biologic therapies due to their superior efficacy and safety profiles. Key trends for the forecast period include improving reimbursement conditions in developed markets, a shift toward biosimilars and cost-effective alternatives, as well as strategic partnerships and product approvals.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the orencia (abatacept) market in the future. Autoimmune disorders occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, resulting in inflammation and damage. This leads to chronic conditions like rheumatoid arthritis and multiple sclerosis, which have causes rooted in both genetic and environmental factors. The rise in autoimmune disorders is attributed to factors such as genetic predisposition, environmental triggers, and greater awareness and diagnosis, leading to more cases being identified. Orencia (abatacept) aids in managing autoimmune diseases by modulating the immune response through selective T-cell costimulation inhibition, thus reducing inflammation and preventing the immune system from attacking healthy tissues. For example, in March 2024, the National Health Council, a U.S.-based non-profit organization, reported that autoimmune diseases affect approximately 50 million Americans, with cases increasing by 3-12% annually. Globally, multiple sclerosis cases rose by 30% in 2022 compared to the previous decade. As a result, the increasing prevalence of autoimmune disorders is contributing to the growth of the orencia (abatacept) market.

The rise of personalized medicine is expected to fuel the growth of the orencia (abatacept) market. Personalized medicine involves tailoring treatment and healthcare strategies to an individual’s unique genetic makeup, environment, and lifestyle to achieve the most precise and effective outcomes. The growth of personalized medicine is driven by advancements in genomic technologies, a better understanding of molecular biology, the increased availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while reducing side effects. Orencia (abatacept) plays a role in personalized medicine by targeting specific immune system pathways involved in autoimmune diseases, allowing for customized treatment plans that minimize systemic side effects and optimize therapeutic results based on a patient’s unique immune response and disease characteristics. For example, in 2023, the Personalized Medicine Coalition, a U.S.-based organization, reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, and over the prior eight years, at least 25% of new drugs had received approval for personalized treatment. Therefore, the rise of personalized medicine is driving the orencia (abatacept) market.

A key trend in the orencia (abatacept) market is the focus on developing innovative drugs to enhance treatment effectiveness, improve patient outcomes, and address unmet needs in managing autoimmune diseases. Abatacept is a biologic medication used in the treatment of juvenile psoriatic arthritis (JPsA), a rare autoimmune condition affecting children and adolescents, causing joint inflammation and skin lesions. For example, in October 2023, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced that the FDA approved the Biologics Licensing Application (sBLA) for abatacept (Orencia) to treat juvenile psoriatic arthritis (JPsA) in patients aged 2 to 17 years. This approval was based on controlled studies involving both adults and children, utilizing pharmacokinetic data from studies on adults with rheumatoid arthritis and psoriatic arthritis, as well as safety data from clinical trials involving children aged 2 to 17 years with polyarticular juvenile idiopathic arthritis (JIA).

Key player operating in the orencia (abatacept) market is Bristol-Myers Squibb (BMS).

North America was the largest region in the orencia (abatacept) market in 2024. The regions covered in orencia (abatacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the orencia (abatacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Orencia (abatacept) is a prescription medication used to treat certain autoimmune diseases. It is classified as a selective T-cell co-stimulation modulator, which works by suppressing overactive immune responses that cause inflammation and tissue damage.

The key formulations of orencia (abatacept) include prefilled syringes and vials. A prefilled syringe contains a single dose of the medication and is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. These formulations are used for various applications, including rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, and are distributed through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The orencia (abatacept) market research report is one of a series of new reports that provides orencia (abatacept) market statistics, including orencia (abatacept) industry global market size, regional shares, competitors with a orencia (abatacept) market share, detailed orencia (abatacept) market segments, market trends and opportunities, and any further data you may need to thrive in the orencia (abatacept) industry. This orencia (abatacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orencia market consists of sales of abatacept-based biologic therapies, injectable and intravenous solutions, and immunomodulatory treatments. Values in this market are ‘factory gate’ values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (such as wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.